Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer

Biotechnology Progress

Volumn 24, Issue 3, 2008, Pages 540-553

  Purvis, Jeremy ^a   Ilango, Vibitha ^b   Radhakrishnan, Ravi ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; AMINO ACIDS; CELL CULTURE; COMPUTER NETWORKS; METROPOLITAN AREA NETWORKS; MICROFLUIDICS; NETWORK PROTOCOLS;

AKT ACTIVATION; BRANCHED NETWORK; CANCER CELL LINES; CELLULAR INHIBITION; CONSTITUTIVELY ACTIVE (CA); EPIDERMAL GROWTH FACTOR RECEPTOR (EDFR); HOMOGENEOUS MODELS; HYPERSENSITIVE RESPONSE (HR); IN ORDER; LUNG CANCERS; MOLECULAR RESOLUTION; MUTANT CELL LINES; TYROSINE KINASE INHIBITORS; WILD-TYPE (WT);

CELL GROWTH;

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; CONFERENCE PAPER; DOSE RESPONSE; DRUG ANTAGONISM; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 45349107336     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp070405o     Document Type: Conference Paper

References (85)

1. Citri, A.; Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7(7), 505-516.
2. Sordella, R., et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305(5687), 1163-1167.
3. Carey, K. D., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006, 66(16), 8163-8171.
4. Chen, Y. R., et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006, 25(8), 1205-1215.
5. Paez, J. G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.[see comment]. Science 2004, 304(5676), 1497-1500.
6. Lynch, T. J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350(21), 2129-2139.
7. Choi, S. H.; Mendrola, J. M.; Lemmon, M. A. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 2006.
8. Shih, A., et al. Network of stabilizing hydrogen bonds is integral to the dimer-mediated allosteric activation mechanism in the ErbB1 and ErbB4 kinase. Submitted for publication, 2008.
9. Liu, Y., et al. A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations. Ann. Biomed. Eng. 2007, 35(6), 1012-1025.
10. Lynch, T. J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. [see comment]. N. Engl. J. Med. 2004, 350(21), 2129-2139.
11. Noro, R., et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 2006, 6, 277.
12. Sharma, S. V., et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10(5), 425-435.
13. Hendriks, B. S., et al. Decreased internalisation of ErbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. Systems Biology, IEE Proc. 2006, 153(6), 457-466.
14. Liu, Y., et al. A multiscale computational approach to dissect early events in the erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations. Ann. Biomed. Eng. 2007, 35, 1012-1025.
15. Schlessinger, J. Common and distinct elements in cellular signaling between EGF and FGF receptors. Science 2004, 306, 1506-1507.
16. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
17. Jorrinssen, R. N. Epidermal growth factor receptor: mechanism of activation and signaling. Exp. Cell Res. 2003, 284, 31-53.
18. Shawyer, L. K.; Slamon, D.; Ullrich, A. A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cell 2002, 1, 117-123.
19. Chatterjee, A., et al. Binomial distribution based tau-leap accelerated stochastic simulation. J. Chem. Phys. 2005, 122, 024112.
20. A. C., et al. Binomial distribution based tau-leap accelerated stochastic simulation. J. Chem. Phys. 2005, 024112.
21. Kholodenko, B. N., et al. Quantification of short term signaling by the epidermal growth factor receptor. J. Biol. Chem. 1999, 274 (42), 30169-30181.
22. Aksan, I.; Kurnaz, M. L. Computer-based model for the regulation of MAPK activation. J. Recept. Signal Transduction Res. 2003, 23, 197-209.
23. Asthagiri, A.; Lauffenburger, D. A. Cell signaling models in bioengineering. Annu. Rev. Biomed. Eng. 2000, 2, 32-53.
24. Miller, J. H.; Zhang, F. Large scale simulation of cellular signaling processes. Parallel Comput. 2004.
25. Schoeberl, B., et al. Computational modeling of the dynamics of MAPKinase cascade activated by surface and internalized receptors. Nat. Biotechnol. 2002, 20, 370-375.
26. Canteley, L. C. The PI3K pathway. Science 2002, 296, 1655-1657.
27. Brown, K. S., et al. The statistical mechanics of complex signaling networks: nerve growth factor signaling. Phys. Biol. 2004, 1, 184-195.
28. Hatakeyama, M., et al. A computational model on the modulation of MAPK and Akt pathways in Heregulin-induced ERB signaling. Biochem. J. 2003, 373, 451-463.
29. Rodrigues, G. A., et al. A Novel Positive Feedback Loop Mediated by the Docking Prote in Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling. Mol. Cell Biol. 2000, 20, 1448-1459.
30. Sachsenmaler, C. Targeting protein kinases for tumor therapy. Onkologie 2001, 24, 346-355.
31. Mendelsohn, J.; Baselga, J. Status of EGFR antagonists in biology and treatment of cancer. J. Clin. Oncol. 2003, 21, 2782-2799.
32. Pulverer, B. Nature insight: Cancer. Nature 2003, 411, 335-395.
33. Uyemura, T., et al. Single-molecule analysis of epidermal growth factor signaling that leads to ultrasensitive calcium response. Biophys. J. 2005.
34. Bhalla, U. S.; Ram, P. T.; Iyengar, R. MAPKinase phosphotase as a locus of flexibility in a mitogen activated protein kinase signaling network. Science 2002, 297, 1018-1023.
35. Bhalla, U. S.; Iyengar, R. Emergent properties of biological networks. Science 1999, 283, 381-387.
36. Weng, G.; Bhalla, U. S.; Iyengar, R. Complexities in biological signaling systems. Science 1999, 284, 92-96.
37. Haugh, J. M.; Wells, A.; Lauffenburger, D. A. Mathematical modeling of epidermal growth factor receptor signaling through the phospholipase C pathway: mechanistic insights and predictions for molecular interventions. Biotechnol. Bioeng. 2000, 70 (2), 225-238.
38. Boerner, J. L., et al. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochromec oxidase subunit II. Mol. Cell Biol. 2004, 24, 7059-7071.
39. Kloth, M. T., et al. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J. Biol. Chem. 2003, 278, 1671-1679.
40. Biscardi, J. S., et al. c-Src-Mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 1999, 274(12), 8335-8343.
41. Wu, W., et al. Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. J. Biol. Chem. 2002, 277 (27), 24252-24257.
42. Haugh, J. M.; Lauffenburger, D. A. Analysis of receptor internalization as a mechanism for modulating signal transduction. J. Theor. Biol. 1998, 195 (2), 187-218.
43. Vieira, A. V.; Lamaze, C.; Schmid, S. L. Control of EGF Receptor signaling by clathrim-mediated endocytosis. Science 1996, 274, 2066-2089.
44. Dikic, I. Mechanisms controlling EGF receptor endocytosis and degradation. Biochem. Soc. Trans. 2003, 31, 1178-1181.
45. Kim, J., et al. Regulation of EGFR internalization by GPCR. Biochemistry 2003, 42, 2887-2894.
46. Pierce, K. L., et al. Role of endocytosis in the activation of extracellular signal-regulated kinase cascade by sequestering and nonsequestering GPCR. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1489-1494.
47. Luttrell, L. M.; Daaka, Y.; Lefkowitz, R. J. Regulation of tyrosine kinase cascades by GPCR. Curr. Opin. Cell Biol. 1999, 11, 177-183.
48. Bookout, A. L., et al. Targeting G β γ signaling to inhibit prostate tumor formation and growth. J. Biol. Chem. 2003, 278, 37569-37573.
49. Prenzel, N., et al. Tyrosine kinase signalling in breast cancer epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2000, 2, 184-190.
50. Cabodi, S., et al. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem. Soc. Trans. 2004, 32, 438-442.
51. Fischer, O. M., et al. EGFR signal trans activation in cancer cells. Biochem. Soc. Trans. 2003, 31, 1203-1208.
52. Saso, K., et al. Differential inhibition of epidermal growth factor signaling pathways in rat hepatocytes by long-term ethanol treatment. Gastroenterology 1997, 112 (6), 2073-2088.
53. Schulze, W. X.; Deng, L.; Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 2005, 1.
54. Mulloy, R., et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007, 67 (5), 2325-2330.
55. Zhang, X., et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125 (6), 1137-1149.
56. Brignola, P. S., et al. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains - Demonstration of differential sensitivity to kinase inhibitors. J. Biol. Chem. 2002, 277(2), 1576-1585.
57. Fan, Y. X., et al. Ligand regulates epidermal growth factor receptor kinase specificity - Activation increases preference for GAB1 and SHC versus autophosphorylation sites. J. Biol. Chem. 2004, 279 (37), 38143-38150.
58. Brignola, P. S., et al. Comparison of biochemical and kinetic properties of type 1 receptor tyrosine kinase intracellular domains. J. Biol. Chem. 2001, 277, 1576-1581.
59. Zhang, X. W., et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125 (6), 1137-1149.
60. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277 (48), 46265-46272.
61. Dill, K. A. Molecular Driving Forces; Garland Science: New York, 2003.
62. Zhou, H. X. Loops in proteins can be modeled as worm-like chains. J. Phys. Chem. B 2001, 105 (29), 6763-6766.
63. Zhang, Y., et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 2005, 4 (9), 1240-1250.
64. Press, W. H., et al. Numerical Recipes, the Art of Scientific Computing; Cambridge Univ. Press: Cambridge, England, 1986.
65. Tracy, S., et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004, 64 (20), 7241-7244.
66. Wells, A., et al. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 1990, 247 (4945), 962-964.
67. Radhakrishnan, R. Molecular systems biology: bridging the gap through multiscale modeling and high-performance computing. Mol. Biosyst. 2008, submitted for publication.
68. Weinstein, I. B.; Joe, A. K. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 2006, 3 (8), 448-457.
69. Weinstein, I. B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297 (5578), 63-64.
70. Duesbery, N.; Vande Woude, G. BRAF and MEK mutations make a late entrance. Sci. STKE 2006, 2006 (328), pe15.
71. Bentires-Alj, M., et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat. Med. 2006, 12(1), 114-21.
72. Mascaux, C., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer 2005, 92(1), 131-9.
73. Samuels, Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304 (5670), 554.
74. Sjoblom, T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314 (5797), 268-274.
75. Janmaat, M. L., et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 2003, 9(6), 2316-2326.
76. Venter, H., et al. An ABC transporter with a secondary-active multidrug translocator domain. Nature 2003, 426, 866-870.
77. Blencke, S.; Ullrich, A.; Daub, H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 2003, 278 (17), 15435-15440.
78. Bing Liu, B. B. J. H. W. Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations. Proteins: Struct. Funct. Bioinformatics 2006, 65(2), 331-346.
79. Engelman, J. A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316 (5827), 1039-1043.
80. Sergina, N. V., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445 (7126), 437-441.
81. Kholodenko, B. N. Cell-signalling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 2006, 7(3), 165-176.
82. Waterman, H.; Yarden, Y. Molecular mechanisms underlying endocytosis and sorting of Erb receptor tyrosine kinases. FEBS letters 2001, 490, 142-152.
83. Lee, J. W., et al. ERBB2 kinase domain mutation in a gastric cancer metastasis. APMIS 2005, 113 (10), 683-687.
84. Lee, J. W., et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res. 2006, 12 (1), 57-61.
85. Krauss, G. Biochemistry of Signal Transduction and Regulation, 3rd ed.; Weinheim: Wiley-VCH, 2003.